<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323778</url>
  </required_header>
  <id_info>
    <org_study_id>25107</org_study_id>
    <nct_id>NCT00323778</nct_id>
  </id_info>
  <brief_title>Prospective Assessment of the Efficacy of Hyaluronate Knee Injections in Patients With Osteoarthritis</brief_title>
  <official_title>Prospective Assessment of the Efficacy of Intra-Articular Hyaluronate to Affect Extracellular Matrix Changes in Patients With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <brief_summary>
    <textblock>
      This study looks at the effect of an injectable medication called Hyalgan on the cartilage of&#xD;
      the knee in people who have osteoarthritis (&quot;wear and tear arthritis&quot;) of the knee. Hyalgan&#xD;
      is a medication which is injected into the knee, and is FDA approved to treat knee arthritis.&#xD;
      We will be using magnetic resonance imaging (MRI) and x-rays to look at knee cartilage to see&#xD;
      how it responds over the course of a year to the injections. A comparison to patients taking&#xD;
      oral pain medication will be made.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyalgan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 45-90&#xD;
&#xD;
          -  seeking medical care for painful knee osteoarthritis&#xD;
&#xD;
          -  alignment based on AP standing radiographs of neutral to 10º of valgus&#xD;
&#xD;
          -  no prior surgery on the ipsilateral knee&#xD;
&#xD;
          -  no history of major trauma to either knee or either hip&#xD;
&#xD;
          -  no history of congenital hip dysplasia&#xD;
&#xD;
          -  No history of inflammatory synovitis or crystalline arthropathy&#xD;
&#xD;
          -  No history of systemic rheumatic disease&#xD;
&#xD;
          -  cruciate and collateral ligament stability, defined by clinical examination&#xD;
&#xD;
          -  meniscus intact (MRI grade II degenerative signal acceptable)&#xD;
&#xD;
          -  Noyes compartment score: no greater than 50% of cartilage thickness over an area&#xD;
             greater than 15mm&#xD;
&#xD;
          -  If bilateral OA, the most painful knee, (as documented by VAS scale for pain) which&#xD;
             qualifies for the study will be entered.&#xD;
&#xD;
          -  If taking glucosamine chondroitin sulfate, discontinue at least one month prior to HA&#xD;
             injections&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous IA HA injection in the ipsilateral knee&#xD;
&#xD;
          -  IA steroid in the ipsilateral knee in the past 3 months&#xD;
&#xD;
          -  MR evidence of inflammatory or hypertrophic synovitis&#xD;
&#xD;
          -  Large joint effusion with a ballotable patella on baseline clinical exam&#xD;
&#xD;
          -  Inability to safely perform MR imaging&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Active malignancy (except non-melanomatous skin cancer)&#xD;
&#xD;
          -  Allergies to HA or chicken products&#xD;
&#xD;
          -  Clinical symptoms of an acute meniscal tear (locking, new acute mechanical symptoms&#xD;
             etc…)&#xD;
&#xD;
          -  A recent injury to the knee&#xD;
&#xD;
          -  Radiographic evidence of Grade III or IV Kellgren and Lawrence OA&#xD;
&#xD;
          -  Chondrocalcinosis on radiographs&#xD;
&#xD;
          -  Unwilling to discontinue or avoid glucosamine chondroitin sulfate for the 12 month&#xD;
             study period&#xD;
&#xD;
          -  People taking blood thinners or who have bleeding problems&#xD;
&#xD;
          -  Anticipated lower extremity surgery during the next 12 months&#xD;
&#xD;
          -  BMI &gt;30 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa A Mandl, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>May 8, 2006</study_first_submitted>
  <study_first_submitted_qc>May 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <last_update_submitted>February 4, 2008</last_update_submitted>
  <last_update_submitted_qc>February 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lisa A. Mandl MD MPH</name_title>
    <organization>Hospital for Special Surgery</organization>
  </responsible_party>
  <keyword>hyalgan</keyword>
  <keyword>knee</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

